Intra-cellular Company Profile
✉ Email this page to a colleague
What is the competitive landscape for INTRA-CELLULAR, and what generic alternatives to INTRA-CELLULAR drugs are available?
INTRA-CELLULAR has one approved drug.
There are eighteen US patents protecting INTRA-CELLULAR drugs.
There are one hundred and thirty-eight patent family members on INTRA-CELLULAR drugs in twenty countries.
Summary for Intra-cellular
International Patents: | 138 |
US Patents: | 18 |
Tradenames: | 1 |
Ingredients: | 1 |
NDAs: | 1 |
Drugs and US Patents for Intra-cellular
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Intra-cellular | CAPLYTA | lumateperone tosylate | CAPSULE;ORAL | 209500-002 | Apr 22, 2022 | RX | Yes | No | 11,052,084 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Intra-cellular | CAPLYTA | lumateperone tosylate | CAPSULE;ORAL | 209500-003 | Apr 22, 2022 | RX | Yes | No | RE48825 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Intra-cellular | CAPLYTA | lumateperone tosylate | CAPSULE;ORAL | 209500-002 | Apr 22, 2022 | RX | Yes | No | 9,199,995 | ⤷ Sign Up | ⤷ Sign Up | ||||
Intra-cellular | CAPLYTA | lumateperone tosylate | CAPSULE;ORAL | 209500-002 | Apr 22, 2022 | RX | Yes | No | 10,695,345 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Intra-cellular | CAPLYTA | lumateperone tosylate | CAPSULE;ORAL | 209500-002 | Apr 22, 2022 | RX | Yes | No | 9,956,227 | ⤷ Sign Up | ⤷ Sign Up | ||||
Intra-cellular | CAPLYTA | lumateperone tosylate | CAPSULE;ORAL | 209500-003 | Apr 22, 2022 | RX | Yes | No | 10,117,867 | ⤷ Sign Up | ⤷ Sign Up | ||||
Intra-cellular | CAPLYTA | lumateperone tosylate | CAPSULE;ORAL | 209500-002 | Apr 22, 2022 | RX | Yes | No | 10,464,938 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Intra-cellular
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Intra-cellular | CAPLYTA | lumateperone tosylate | CAPSULE;ORAL | 209500-001 | Dec 20, 2019 | 7,183,282 | ⤷ Sign Up |
Intra-cellular | CAPLYTA | lumateperone tosylate | CAPSULE;ORAL | 209500-001 | Dec 20, 2019 | RE39680 | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Intra-cellular Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Canada | 2725342 | ⤷ Sign Up |
South Korea | 20200134341 | ⤷ Sign Up |
South Korea | 101981840 | ⤷ Sign Up |
Japan | 6773837 | ⤷ Sign Up |
South Korea | 20150140418 | ⤷ Sign Up |
European Patent Office | 2320731 | ⤷ Sign Up |
South Korea | 20210049200 | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.